iStent Inject New Enrollment Post-Approval Study

Status unconfirmed · Not applicable

Conditions studied: Glaucoma, Open-Angle, Glaucoma

In brief

Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.

Key facts

Study ID

NCT04624698

Run by

Glaukos Corporation

People needed

358

Starts

2020-09-22

Expected to finish

2026-05-01

Last updated by the study team

2024-02-23

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥ 22 years of age
• Mild to moderate primary open-angle glaucoma
• Scheduled to undergo cataract surgery
• Able and willing to attend scheduled follow-up exams for three years postoperatively
• Able and willing to provide written informed consent on the IRB approved Informed Consent Form
• Operative Inclusion Criterion:
• Successful, uncomplicated cataract surgery

You may not qualify if…

• Angle closure glaucoma
• Traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle
• Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure

Where it is running

• Eye Doctors of Arizona, PLLC — Phoenix, Arizona, United States
• Wolstan and Goldberg Eye Associates — Torrance, California, United States
• Glaucoma Associates of Texas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.